JS014 / Shanghai Junshi Biosci, Anwita Biosci - LARVOL DELTA

JS014 Combined With Toripalimab and TACE in Unresectable HCC: a Phase Ib Study (clinicaltrials.gov) - P1 | N=20 | Enrolling by invitation | Sponsor: Xiangya Hospital of Central South University | Not yet recruiting ➔ Enrolling by invitation | Trial completion date: May 2027 ➔ Jul 2029 | Initiation date: Mar 2025 ➔ Jul 2025 | Trial primary completion date: Jan 2026 ➔ Jan 2027

Enrollment open • Trial completion date • Trial initiation date • Trial primary completion date • Hepatocellular Cancer • Oncology • Solid Tumor

JS014 Combined With Toripalimab and TACE in Unresectable HCC: a Phase Ib Study (clinicaltrials.gov) - P1 | N=20 | Not yet recruiting | Sponsor: Xiangya Hospital of Central South University

New P1 trial • Hepatocellular Cancer • Oncology • Solid Tumor

Phase 1 First-in-human Study of JS014 (clinicaltrials.gov) - P1 | N=60 | Recruiting | Sponsor: Anwita Biosciences | Active, not recruiting ➔ Recruiting

Combination therapy • Enrollment open • Hematological Malignancies • Lymphoma • Oncology • Solid Tumor

A Phase 1 First-in-human Study of JS014 (clinicaltrials.gov) - P1 | N=60 | Active, not recruiting | Sponsor: Anwita Biosciences

Combination therapy • New P1 trial • Hematological Malignancies • Lymphoma • Oncology • Solid Tumor

Junshi Biosciences Announces NMPA Acceptance of Investigational New Drug Application for JS014 (GlobeNewswire) - "Junshi Biosciences...announced...that the National Medical Products Administration (NMPA) has accepted its Investigational New Drug (IND) application for JS014....Preclinical studies demonstrate that JS014 and JS001 (toripalimab) have strong synergistic antitumor effect."

Non-US regulatory • Preclinical • Oncology